MassDevice

Rivermark Medical brings in $20M to support FloStent device for BPH

Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker ...

Rivermark pockets $20m in Series D for late-stage prostate device trial

The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...

Andera Partners Leads $20 Million Series D Financing in Rivermark Medical

The FloStent™ System Promises to Redefine the BPH Care PathwayParis, France, and Milwaukee, WI, US, May 13, 2026 (GLOBE ...

Water Vapour Therapy: A Minimally Invasive Breakthrough In Prostate Care

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is a common condition affecting aging men in India. It often ...
PharmiWeb

Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market 2026 Analysis & Forecast To 2031 By Key Players, Share, Trend, Segmentation, Top Leaders and Regi…

Benign Prostatic Hyperplasia Surgical Treatment Market OverviewThe global benign prostatic hyperplasia surgical treatment ...
Seeking Alpha

Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMXF) [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been ...